bluebird bio flying high on CAR-T results

2 December 2016

US biotech bluebird bio (Nasdaq: BLUE) saw its share price shoot up by nearly 14% to $68.65 on Thursday following the announcement of interim Phase I dose escalation data for its anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma.

The overall response rate with those who took bb2121 was 78%, including patients with stringent complete responses and elimination of minimal residual disease, a promising finding for bluebird bio and its partner in the program, fellow US biotech firm Celgene (Nasdaq: CELG).

David Davidson, chief medical officer at bluebird bio, said: “We are pleased that these early data from our ongoing Phase I study of bb2121 demonstrate objective anti-tumor responses in heavily pre-treated patients with multiple myeloma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK